Trial Profile
Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluate the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Lenvervimab (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GC Biopharma
- 29 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2018 Status changed from planning to recruiting.
- 19 Jan 2018 New trial record